Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
NCT04434040
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: Sacituzumab govitecan Atezolizumab
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
- Triple Negative Breast Cancer
- Residual Cancer
- Circulating Tumor DNA
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Dana-Farber Cancer Institute
- Last updated on ClinicalTrials.gov
- May 4, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California San Francisco · San Francisco, CA
Massachusetts · 1
- Dana-Farber Cancer Institute · Boston, MA
Pennsylvania · 1
- University of Pennsylvania-Abramson Cancer Center · Philadelphia, PA
Tennessee · 1
- Vanderbilt-Ingram Cancer Center · Nashville, TN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.